首页 / 院系成果 / 成果详情页

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung 期刊论文 会议论文

编号：

307f5c41-1811-417f-aba6-235207f9e36a
作者：

Wu, YiLong(吴一龙)#^[1,2]Zhou, Caicun(周彩存)^[3]Hu, ChengPing(胡成平)^[4]Feng, Jifeng(冯继锋)^[5]Lu, Shun(陆舜)^[6]Huang, Yunchao(黄云超)^[7]Li, Wei(李薇)^[8]Hou, Mei^[9];Shi, Jian Hua^[10];Lee, Kye Young^[11]Massey, Dan^[12];Shi, Yang^[13];Chen, JiongJie Jack^[13];Zazulina, Victoria^[12]Geater, Sarayut L.^[14];
语种：

英文
期刊：

EUROPEAN RESPIRATORY JOURNAL ISSN：0903-1936 2013 年 42 卷 ; SEP 1
收录：
推荐引用方式
GB/T 7714：

Wu Yi-Long,Zhou Caicun,Hu Cheng-Ping, et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung [J].EUROPEAN RESPIRATORY JOURNAL,2013,42.
APA：

Wu Yi-Long,Zhou Caicun,Hu Cheng-Ping,Feng Jifeng,&Geater Sarayut L..(2013).LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung .EUROPEAN RESPIRATORY JOURNAL,42.
MLA：

Wu Yi-Long, et al. "LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung" .EUROPEAN RESPIRATORY JOURNAL 42(2013).
入库时间：

1/1/2013 12:00:00 AM
更新时间：

1/1/2013 12:00:00 AM

浏览次数：11  下载次数：0

分享到：

浏览次数：11

下载次数：0

打印次数：0

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung 期刊论文 会议论文

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung 期刊论文会议论文